Table 1 Antibiotic susceptibility profiles of K. pneumoniae. The results of antimicrobial susceptibility testing - antibiotics MIC (mg/L) and breakpoint interpretation or epidemiological cut-off value
Isolates | 1566D | 1567D | 2035D | 2036D | 2037D | 2038D | 2039D | 2040D |
|---|---|---|---|---|---|---|---|---|
source | sputum | bile | sputum | sputum | blood | sputum | sputum | environment |
Infection | Pulmonary | Abdominal | Pulmonary | Pulmonary | Pulmonary | Pulmonary | Pulmonary | N/A |
ampicillin | ≥32(R) | ≥32(R) | ≥32(R) | ≥32(R) | ≥32(R) | ≥32(R) | ≥32(R) | ≥32(R) |
ampicillin/sulbactam | ≥32(R) | ≥32(R) | ≥32(R) | ≥32(R) | ≥32(R) | ≥32(R) | ≥32(R) | ≥32(R) |
piperacillin/tazobactam | ≥128(R) | ≥128(R) | ≥128(R) | ≥128(R) | ≥128(R) | ≥128(R) | ≥128(R) | ≥128(R) |
cefazolin | ≥64(R) | ≥64(R) | ≥64(R) | ≥64(R) | ≥64(R) | ≥64(R) | ≥64(R) | ≥64(R) |
cefotetan | ≥64(R) | ≥64(R) | ≥64(R) | ≥64(R) | ≥64(R) | ≥64(R) | ≥64(R) | ≥64(R) |
ceftazidime | ≥64(R) | ≥64(R) | ≥64(R) | ≥64(R) | ≥64(R) | ≥64(R) | ≥64(R) | ≥64(R) |
ceftriaxone | ≥64(R) | ≥64(R) | ≥64(R) | ≥64(R) | ≥64(R) | ≥64(R) | ≥64(R) | ≥64(R) |
cefepime | ≥64(R) | ≥64(R) | ≥64(R) | ≥64(R) | ≥64(R) | ≥64(R) | ≥64(R) | ≥64(R) |
aztreonam | ≥64(R) | ≥64(R) | ≥64(R) | ≥64(R) | ≥64(R) | ≥64(R) | ≥64(R) | ≥64(R) |
imipenem | ≥16(R) | ≥16(R) | ≥16(R) | ≥16(R) | ≥16(R) | ≥16(R) | ≥16(R) | ≥16(R) |
amikacin | ≥64(R) | ≤4(S) | ≥64(R) | ≥64(R) | ≥64(R) | ≥64(R) | ≥64(R) | ≥64(R) |
gentamicin | ≥16(R) | ≥16(R) | ≥16(R) | ≥16(R) | ≥16(R) | ≥16(R) | ≥16(R) | ≥16(R) |
tobramycin | ≥16(R) | ≤2(S) | ≥16(R) | ≥16(R) | ≥16(R) | ≥16(R) | ≥16(R) | ≥16(R) |
ciprofloxacin | ≥4(R) | ≥4(R) | ≥4(R) | ≥4(R) | ≥4(R) | ≥4(R) | ≥4(R) | ≥4(R) |
levofloxacin | ≥8(R) | ≥8(R) | ≥8(R) | ≥8(R) | ≥8(R) | ≥8(R) | ≥8(R) | ≥8(R) |
macrodantin | 256(R) | 256(R) | ≥512(R) | ≥512(R) | ≥512(R) | ≥512(R) | ≥512(R) | ≥512(R) |
sulfamethoxazole/trimethoprim | ≥320(R) | ≤20(S) | ≤20(S) | ≤20(S) | ≤20(S) | ≥320(R) | ≥320(R) | ≥320(R) |